CLARIVATE PLC — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Clarivate completed the sale of its Life Sciences & Healthcare (LS&H) segment on October 6, 2026, for net cash proceeds of $488.4 million. Post-divestiture, the company now focuses on two segments: Academia & Government (~$1.2B revenue, 95% recurring) and Intellectual Property (~$0.8B revenue, 90% recurring). Q3 2026 continuing operations revenues were $481.6M (organic growth +0.4%); adjusted EBITDA $218.2M (45.3% margin); adjusted EPS $0.21. FY2026 guidance updated: revenues $1.965–$1.985B, adjusted EBITDA $865–$885M, free cash flow $320–$340M.
Why this rating
Portfolio transformation materially reshapes business model toward higher-margin recurring revenue (~93% mix). $488M proceeds and $293M YTD debt reduction improve leverage (now ~4x, targeting 3.5–3.6x). Organic growth stabilizing; AI initiatives gaining traction. Relative to $1.3B market cap, divestiture eliminates a dragging segment, sharpens strategy, and creates cash for deleveraging—meaningful but not transformational in isolation.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.